Two different types of supplements are glomming onto the popularity of GLP-1 agonist drugs like semaglutide and tirzepatide, which mimic a natural appetite-suppressing, blood-sugar-regulating hormone called glucagon-like peptide-1. First, there’s a rise in efforts to market supplements as complementary to GLP-1 drugs.
Supergut CEO Marc Washington told WIRED that the company’s sales in 2024 were three to four times previous years’ sales as a result of increased interest in non-pharmaceutical ways to increase GLP-1 production. Some health experts question whether these offerings are worthwhile.
เราได้สรุปข่าวนี้มาให้อ่านอย่างรวดเร็ว หากสนใจข่าว สามารถอ่านฉบับเต็มได้ที่นี่ อ่านเพิ่มเติม:
ประเทศไทย ข่าวล่าสุด, ประเทศไทย หัวข้อข่าว
Similar News:คุณยังสามารถอ่านข่าวที่คล้ายกันนี้ซึ่งเรารวบรวมจากแหล่งข่าวอื่น ๆ ได้
Ozempic And Wegovy Rivals: Here Are The Companies Working On Competitor Weight Loss DrugsRobert Hart is a senior reporter for Forbes covering science, technology and health with a frequent focus on artificial intelligence, space, weight loss drugs and emerging technologies. He joined Forbes in 2020 and is based in London. Rob has covered everything from the billionaire space race, the health impacts of overturning Roe v.
แหล่ง: ForbesTech - 🏆 318. / 59 อ่านเพิ่มเติม »
Ozempic And Wegovy Rivals: Here Are The Companies Working On Competitor Weight Loss DrugsRobert Hart is a senior reporter for Forbes covering science, technology and health with a frequent focus on artificial intelligence, space, weight loss drugs and emerging technologies. He joined Forbes in 2020 and is based in London. Rob has covered everything from the billionaire space race, the health impacts of overturning Roe v.
แหล่ง: Forbes - 🏆 394. / 53 อ่านเพิ่มเติม »
For companies in the Ozempic-fueled weight-loss economy, it's survival of the fittestAs powerful anti-obesity drugs become more widely available, companies are repositioning themselves with new products and services.
แหล่ง: latimes - 🏆 11. / 82 อ่านเพิ่มเติม »